A two-year period for selling bufexamac-contianing products cannot be granted according to BfArM’s Feststellungsbescheid (ascertainment decision). Prior to the BfArM order the authorisation holders had abandoned their marketing authorisations in Germany.

risk information - full text (available in German only)